ubiquinone has been researched along with Hypothyroidism* in 13 studies
1 review(s) available for ubiquinone and Hypothyroidism
1 trial(s) available for ubiquinone and Hypothyroidism
12 other study(ies) available for ubiquinone and Hypothyroidism
Article | Year |
---|---|
Relationship between plasma antioxidants and thyroid hormones in chronic obstructive pulmonary disease.
A low-T₃ syndrome is observed in chronic diseases, but its treatment is still debated. Chronic obstructive pulmonary disease (COPD) has not been conclusively studied under this aspect. COPD is a complex condition, which cannot be considered a lung-related disorder, but rather a systemic disease also associated to increased oxidative stress. We evaluated thyroid hormones and antioxidant systems, the lipophilic Coenzyme Q10 (CoQ₁₀) and total antioxidant capacity (TAC) in COPD patients to reveal the presence of a low-T₃ syndrome in COPD and investigate the correlation between thyroid hormones, lung function parameters and antioxidants.. We studied: 32 COPD patients and 45 controls, evaluating thyrotropin (TSH), free-triiodotyronine (fT₃), free-tetraiodotyronine (fT₄), CoQ₁₀ (also corrected for cholesterol) and TAC. CoQ₁₀ was assayed by HPLC; TAC by the metmyoglobin-ABTS method and expressed as latency time (LAG) in radical species appearance.. We found significantly lower LAG values, fT₃ and fT₄ levels and significantly higher TSH in COPD patients vs. controls. LAG values significantly correlated with fT₃ concentration. 12 out of 32 patients exhibited fT₃ levels lower than normal range. So we divided COPD patients in 2 groups on the basis of the fT₃ concentration (normal fT₃ COPD and low fT₃ COPD). We observed lower LAG values in normal fT₃-COPD, compared to healthy subjects, with a further significant reduction in low fT₃-COPD patients. Moreover higher TSH concentration was present in normal fT₃-COPD, compared to healthy subjects, with a further significant increase in low fT₃-COPD patients. CoQ₁₀/cholesterol ratio was higher in low fT₃-COPD vs. normal fT₃-COPD, with a nearly significant difference.. These data seem to indicate an increased oxidative stress in low fT₃-COPD and a role of fT₃ in modulating antioxidant systems. However low fT₃ levels are joined to metabolic indexes of true hypothyroidism, suggesting that elevated CoQ₁₀ expresses a reduced tissue utilization. These data might suggest the need of thyroid replacement therapy in such a condition. Topics: Aged; Aged, 80 and over; Antioxidants; Cholesterol; Female; Humans; Hypothyroidism; Italy; Lung; Male; Middle Aged; Oxidative Stress; Prevalence; Pulmonary Disease, Chronic Obstructive; Regression Analysis; Thyroid Hormones; Thyrotropin; Thyroxine; Triiodothyronine; Ubiquinone | 2012 |
Evaluation of antioxidant systems in pituitary-adrenal axis diseases.
The role of adrenal steroids in antioxidant regulation is not known. Previously, we demonstrated some Coenzyme Q(10) (CoQ(10)) alterations in pituitary diseases, which can induce complex pictures due to alterations of different endocrine axes. Therefore we determined CoQ(10) and Total Antioxidant Capacity (TAC) in pituitary-dependent adrenal diseases: 6 subjects with ACTH-dependent adrenal hyperplasia (AH); 19 with secondary isolated hypoadrenalism (IH), 19 with associated hypothyroidism (multiple pituitary deficiencies, MPH). CoQ(10) was assayed by HPLC; TAC by the system metmyoglobin-H(2)O(2), which, interacting with the chromogenous 2,2(I)-azinobis-(3-ethylbenzothiazoline-6-sulphonate), generates a spectroscopically revealed radical compound after a latency time (Lag) proportional to the antioxidant content. CoQ(10) levels were significantly lower in IH than AH and MPH, with a similar trend when adjusted for cholesterol. Also TAC was lower in IH than in AH and MPH, suggesting that adrenal hormones can influence antioxidants. However, since thyroid hormones modulate CoQ(10) levels and metabolism, when thyroid deficiency coexists it seems to play a prevalent influence. Topics: Adrenal Hyperplasia, Congenital; Adrenal Insufficiency; Antioxidants; Chromatography, High Pressure Liquid; Humans; Hypothyroidism; Pituitary-Adrenal System; Ubiquinone | 2010 |
Coenzyme Q10 evaluation in pituitary-adrenal axis disease: preliminary data.
In previous works we have demonstrated plasma CoQ10 alterations in pituitary diseases, such as acromegaly or secondary hypothyroidism. However, pituitary lesions can induce complex clinical pictures due to alterations of different endocrine axes controlled by pituitary itself. A further rationale for studying CoQ10 in pituitary-adrenal diseases is related to the common biosynthetic pathway of cholesterol and ubiquinone. We have therefore assayed plasma CoQ10 levels in different conditions with increased or defective activity of pituitary-adrenal axis (3 subjects with ACTH-dependent adrenal hyperplasia, 2 cases of Cushing's disease and 1 case of 17-alpha-hydroxylase deficiency; 10 subjects with secondary hypoadrenalism, including three subjects with also secondary hypothyroidism). CoQ10 levels were significantly lower in isolated hypoadrenalism than in patients with adrenal hyperplasia and multiple pituitary deficiencies (mean +/- SEM: 0.57 +/- 0.04 vs 1.08 +/- 0.08 and 1.10 +/- 0.11 microg/ml, respectively); when corrected for cholesterol levels, the same trend was observed, but did not reach statistical significance. These preliminary data indicate that secretion of adrenal hormones is in some way related to CoQ10 levels, both in augmented and reduced conditions. However, since thyroid hormones have an important role in modulating CoQ10 levels and metabolism, when coexistent, thyroid deficiency seems to play a prevalent role in comparison with adrenal deficiency. Topics: Adrenal Gland Diseases; Adrenal Glands; Adrenal Insufficiency; Adult; Aged; Cholesterol; Coenzymes; Female; Humans; Hydrocortisone; Hyperplasia; Hypothyroidism; Male; Middle Aged; Pituitary Diseases; Pituitary-Adrenal System; Thyroxine; Triiodothyronine; Ubiquinone | 2005 |
Effect of thyroid state on rate and sites of H2O2 production in rat skeletal muscle mitochondria.
The purpose of this study was to investigate the effects of thyroid state on rates and sites of H(2)O(2) production in rat muscle mitochondria. With Complex I- and Complex II-linked substrates, hypothyroidism decreased and hyperthyroidism increased the rates of O(2) consumption during State 4 and State 3 respiration and the rates of H(2)O(2) release during State 4 respiration. During State 3, the rates of H(2)O(2) release were not affected by thyroid state. However, the mitochondrial capacity to remove H(2)O(2) increased in the transition from hypothyroid to hyperthyroid state, thus suggesting that an increase in H(2)O(2) production rate also occurred in such a transition during State 3 respiration. The observation that mitochondrial coenzyme Q levels and cytochrome oxidase activities are higher in the hyperthyroid and lower in the hypothyroid groups suggests that the modifications of H(2)O(2) production are due to a modulation by thyroid hormone of the mitochondrial content of autoxidizable electron carriers. This idea is supported by measurements of H(2)O(2) release in the presence of respiratory inhibitors. In fact, such measurements indicate that the thyroid state-linked changes in H(2)O(2) production occur at both generator sites of the respiratory chain. Topics: Animals; Electron Transport Complex I; Electron Transport Complex IV; Hydrogen Peroxide; Hyperthyroidism; Hypothyroidism; Male; Mitochondria, Muscle; Muscle, Skeletal; NADH, NADPH Oxidoreductases; Oxygen Consumption; Rats; Rats, Wistar; Thyroid Gland; Ubiquinone | 2003 |
Effects of thyroid state on H2O2 production by rat heart mitochondria: sites of production with complex I- and complex II-linked substrates.
This work was designed to determine possible effects of altered thyroid states on rates and sites of H 2 O 2 production by rat heart mitochondria. Rates of O 2 consumption and H 2 O 2 release, capacities to remove the peroxide, lipid peroxidation, cytochrome oxidase activities and ubiquinone levels were determined in heart mitochondria from euthyroid, hypothyroid, and hyperthyroid rats. Hypothyroidism decreased, whereas hyperthyroidism increased the rates of O 2 consumption and H 2 O 2 release during both state 4 and state 3 respiration with Complex I- or Complex II-linked substrates. The percentage of O 2 released as H 2 O 2 was not significantly affected by thyroid state. However, the mitochondrial capacity to remove H 2 O 2 increased in the transition from hypothyroid to hyperthyroid state, which indicates that H 2 O 2 production did not modify in proportion to the rate of O 2 consumption. The thyroid-state-linked changes in H 2 O 2 production were well correlated with the levels of hydroperoxides. Rates of H 2 O 2 release in the presence of respiratory inhibitors indicated that changes in the H 2 O 2 production occurred at both sites at which H 2 O 2 was generated in euthyroid state. This result and the observation that ubiquinol levels and cytochrome oxidase activities increase in the transition from hypothyroid to hyperthyroid state suggest that the modifications of H 2 O 2 production are due to a modulation by thyroid hormone of mitochondrial content of autoxidisable electron carriers. Topics: Animals; Electron Transport; Electron Transport Complex I; Electron Transport Complex II; Hydrogen Peroxide; Hyperthyroidism; Hypothyroidism; Kinetics; Lipid Peroxidation; Male; Mitochondria, Heart; Oxygen Consumption; Rats; Rats, Wistar; Thyroid Gland; Ubiquinone | 2003 |
Effect of thyroid state on susceptibility to oxidants and swelling of mitochondria from rat tissues.
The effects of the thyroid state on oxidative damage, antioxidant capacity, susceptibility to in vitro oxidative stress and Ca(2+)-induced permeabilization of mitochondria from rat tissues (liver, heart, and gastrocnemious muscle) were examined. Hypothyroidism was induced by administering methimazole in drinking water for 15 d. Hyperthyroidism was elicited by a 10 d treatment of hypothyroid rats with triiodothyronine (10 micro g/100 g body weight). Mitochondrial levels of hydroperoxides and protein-bound carbonyls significantly decreased in hypothyroid tissues and were reported above euthroid values in hypothyroid rats after T(3) treatment. Mitochondrial vitamin E levels were not affected by changes of animal thyroid state. Mitochondrial Coenzyme Q9 levels decreased in liver and heart from hypothyroid rats and increased in all hyperthyroid tissues, while Coenzyme Q10 levels decreased in hypothyroid liver and increased in all hyperthyroid tissues. The antioxidant capacity of mitochondria was not significantly different in hypothyroid and euthyroid tissues, whereas it decreased in the hyperthyroid ones. Susceptibility to in vitro oxidative challenge decreased in mitochondria from hypothyroid tissues and increased in mitochondria from hyperthyroid tissues, while susceptibility to Ca(2+)-induced swelling decreased only in hypothyroid liver mitochondria and increased in mitochondria from all hyperthyroid tissues. The tissue-dependence of the mitochondrial susceptibility to stressful conditions in altered thyroid states can be explained by different thyroid hormone-induced changes in mitochondrial ROS production and relative amounts of mitochondrial hemoproteins and antioxidants. We suggest that susceptibilities to oxidants and Ca(2+)-induced swelling may have important implications for the thyroid hormone regulation of the turnover of proteins and whole mitochondria, respectively. Topics: Animals; Antioxidants; Calcium; Hyperthyroidism; Hypothyroidism; In Vitro Techniques; Lipid Peroxidation; Male; Methimazole; Mitochondria, Heart; Mitochondria, Liver; Mitochondria, Muscle; Mitochondrial Swelling; Oxidative Stress; Rats; Rats, Wistar; Triiodothyronine; Ubiquinone; Vitamin E | 2003 |
Effects of the novel thyroid hormone analogues, SKF L-94901, DIBIT, and 3'-AC-T2 on mitochondrial function.
The effects of L-T3 (3,3',5-triiodo-L-thyronine) and three novel analogues, SKF L-94901 (3,5-Dibromo-3'-pyridazinone-L-thyronine), Dibit (3,5-Dibromo-3'-isopropyl-L-thyronine), and 3'-Ac-T2(3'-Acetyl-3,5,-Diiodo-L-thyronine), on mitochondrial parameters were determined in hypothyroid rats. The parameters include the 24 hour hormone-induced changes in the bc1 complex and in the proton permeability of the mitochondrial inner membrane. The cardiac sparing analogue, SKF L-94901, had no effect on mitochondrial respiration or proton permeability; but the analogue did increase a-glycerophosphate dehydrogenase activity, mitochondrial ubiquinone content, and altered the bypass respiration in the bc1 complex. Dibit also did not increase respiration significantly but did change the other parameters. 3'-Ac-T2 increased respiration, mitochondrial ubiquinone content, proton permeability, enzyme activity and altered the bypass of the Antimycin A blockage in the bc1 complex. Topics: Animals; Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone; Cell Membrane; Diiodothyronines; Glycerolphosphate Dehydrogenase; Hypothyroidism; Male; Mitochondria, Heart; Oxygen Consumption; Permeability; Protons; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Thyronines; Ubiquinone | 1996 |
Effects of 3,3',5-triiodo-L-thyronine (L-T3) and T3 analogues on mitochondrial function.
The effects of L-T3 and several analogues on mitochondrial parameters were determined in hypothyroid rats. These parameters include the 24 hour hormone-induced changes in the bc1 complex and in the inner membrane's proton permeability. L-T3, and all analogues except rT3, increased mitochondrial ubiquinone to euthyroid levels. L-T3, D-T3 and 3'IpT2 but not rT3, Triac, Triprop, or Dimit, altered the bypass respiration in the bc1 complex. L-T3, D-T3, Triac, 3'IpT2, and Triprop, but not rT3 or Dimit, increased the membrane's proton permeability. Actinomycin D did not prevent the increase in mitochondrial ubiquinone or the permeability change. The results show the selective thyromimetic properties of the analogues and that some of the mitochondrial changes do not require protein synthesis. Topics: Animals; Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone; Cytochromes c1; Dactinomycin; Electron Transport; Glycerolphosphate Dehydrogenase; Hypothyroidism; Intracellular Membranes; Liver; Male; Mitochondria; Oxygen Consumption; Permeability; Proton Pumps; Rats; Rats, Sprague-Dawley; Triiodothyronine; Triiodothyronine, Reverse; Ubiquinone | 1995 |
[Circulating levels of CoQ10 in hypo- and hyperthyroidism].
Coenzyme Q10 (CoQ10) plays an essential physiologic role in oxidative phosphorylation and its plasma and tissue concentration has been evaluated in various pathologic conditions, both endocrine and non endocrine; among the latter particularly in cardiac failure. Plasma CoQ10 determination has been reported in the literature an a useful diagnostic tool in differential diagnosis of thyroid diseases. In the present study we have evaluated CoQ10 circulating levels both in hypo- and hyperthyroidism. For this purpose plasma CoQ10, fT3-fT4 and TSH concentrations have been determined (HPLC, RIA and IRMA respectively) in a group of hypothyroid patients, hyperthyroid and control subjects. No patient was harbouring cardiovascular, metabolic or systemic disease. CoQ10 has resulted 0.97 +/- 0.46 mcg/ml in the hypothyroid group, 0.51 +/- 0.35 in hyperthyroid and 0.73 +/- 0.16 in control group, with a significative difference between first and second group only; more, the prevalence of high levels has appeared greater in hypo- towards hyperthyroid patients and that of low levels in the latter greater than in the former. Finally an inverse relation of CoQ10 with fT3 and tT3, but not with fT4 and tT4, has been shown. In conclusion, plasma CoQ10 levels have not given in this study a sharp distinction between euthyroidism on a side and hypo- and hyperthyroidism on the other, but necessity of longitudinal studies after therapy is outlined, both to know time of normalization of plasma concentrations and to verify the opportunity of exogenous administration of CoQ10 in hyperthyroid patients with risk factors for heart failure. Topics: Adult; Coenzymes; Female; Humans; Hyperthyroidism; Hypothyroidism; Male; Middle Aged; Ubiquinone | 1994 |
Evaluation of metabolic status in amiodarone-induced thyroid disorders: plasma coenzyme Q10 determination.
In previous works we have demonstrated that Coenzyme Q10 (CoQ10) levels have a significant inverse correlation with thyroid hormone concentration in patients with spontaneous hyper- or hypothyroidism. In order to verify whether this correlation is maintained in patients on long-term amiodarone therapy, in whom thyroid metabolism is altered by the iodine contained in the drug, we have studied 30 patients with thyroid dysfunction induced by chronic amiodarone treatment. We have distinguished four groups of patients: group A (n = 8): patients with true hyperthyroidism induced by drug administration; group B (n = 11): patients with mild hyperthyroid symptoms, but isolated thyroxine increase or dissociation between different indexes of thyroid function; group C (n = 5): patients with normal thyroid hormone levels, but increased TSH levels; group D (n = 6): patients who appeared really clinically euthyroid, with normal thyroid hormone levels and normal TSH response to TRH. In group A patients, plasma CoQ10 levels averaged 0.49 +/- 0.03 micrograms/ml, significantly lower than those in normal subjects and similar to those observed in spontaneous hyperthyroid patients. In group B patients, CoQ10 levels were in the normal range (0.88 +/- 0.10 microgram/ml). In group C patients, CoQ10 levels were lower than those in normal subjects and similar to those of group A patients (0.49 +/- 0.04 microgram/ml); they differed, in regards to CoQ10 values, in comparison with spontaneous primary hypothyroid patients, who had very high levels of plasma CoQ10. Finally, in group D patients, CoQ10 levels were in the normal range (0.77 +/- 0.04 microgram/ml).(ABSTRACT TRUNCATED AT 250 WORDS) Topics: Adult; Aged; Amiodarone; Female; Goiter; Humans; Hyperthyroidism; Hypothyroidism; Male; Middle Aged; Thyroid Gland; Thyrotropin; Thyroxine; Ubiquinone | 1989 |
Serum coenzyme Q10 levels in thyroid disorders.
The correlation between serum CoQ10 levels and serum thyroid hormones in thyroid disorders was investigated in the present studies. Serum CoQ10 was measured by high speed liquid chromatography utilizing ultraviolet detector. In normal controls, serum CoQ10 level of the male was higher than that of the female. Serum CoQ10 level in hyperthyroidism was significantly lower than that of euthyroid subjects. But in hypothyroidism, serum CoQ10 level did not show any significant difference from that of euthyroid subjects. Significant inverse correlations were demonstrated between log CoQ10 and log T3, log T4, log free T4, or log rT3. These data suggested abnormalities in the mitochondrial electron transport system in thyroid disorders. Topics: Adolescent; Adult; Aged; Child; Coenzymes; Female; Humans; Hyperthyroidism; Hypothyroidism; Male; Middle Aged; Thyroid Diseases; Thyroid Hormones; Thyroidectomy; Ubiquinone | 1980 |
Metabolism of ubiquinone in relation to thyroxine status.
1. Under conditions of thyrotoxicosis induced by feeding rats with iodinated casein, ubiquinone concentration was found to increase in the liver by increased synthesis and by partly decreased catabolism leading to its accumulation. The increased ubiquinone was found primarily in the mitochondrial and supernatant fractions. 2. Supplementing the diet with thyroxine, at less than toxic doses, also increased the synthesis and the concentration of ubiquinone in the liver. 3. In the condition of hypothyroidism obtained by feeding rats with thiouracil the concentration and the synthesis of ubiquinone in the liver showed a small decrease. 4. Synthesis of ubiquinone in liver slices was partially inhibited by addition of thyroxine in vitro. Therefore the activation effect on ubiquinone synthesis of excess of thyroxine in the intact animals appears to be by an indirect mechanism. Topics: Animals; Depression, Chemical; Diet; Hyperthyroidism; Hypothyroidism; In Vitro Techniques; Liver; Mitochondria, Liver; Rats; Stimulation, Chemical; Thyroid Diseases; Thyroxine; Ubiquinone | 1969 |